An effective inhibitor of S-adenosylmethionine decarboxylase
Khomutov, R.M.; Zavalova, L.L.; Syrku, V.I.; Artamonova, E.I.; Khomutov, A.R.
Bioorganicheskaia Khimiia 9(1): 130-133
1983
ISSN/ISBN: 0132-3423 PMID: 6333242 Document Number: 212366
New analogues of cAMP, namely 2'-phosphate of cAMP and its esters, were obtained by direct phosphorylation of N6-benzoyladenosine 3',5'-cyclic phosphate with 2-cyanoethyl phosphate in the presence of DCC followed by the removal of protecting groups.
Document emailed within 1 workday
Related Documents
Wang, J.Y.; Viar, M.J.; McCormack, S.A.; Johnson, L.R. 1992: Effect of putrescine on S-adenosylmethionine decarboxylase in a small intestinal crypt cell line American Journal of Physiology 263(4 Pt 1): G494-G501Wainfan, E.; Brody, H.; Relyea, N.M.; Balis, M.E. 1980: Comparisons of liver transfer RNA methyltransferase and adenosylmethionine decarboxylase activities of male and female rats Cancer Research 40(3): 620-624
Slotkin, T.A.; Seidler, F.J.; Trepanier, P.A.; Whitmore, W.L.; Lerea, L.; Barnes, G.A.; Weigel, S.J.; Bartolome, J. 1982: Ornithine decarboxylase and polyamines in tissues of the neonatal rat: effects of alpha-difluoromethylornithine, a specific, irreversible inhibitor of ornithine decarboxylase Journal of Pharmacology and Experimental Therapeutics 222(3): 741-745
Stammler, A.; Vielhaber, K. 1972: Therapy of Parkinsonism using L-dopa in combination with a decarboxylase inhibitor Fortschritte der Neurologie Psychiatrie und Ihrer Grenzgebiete 40(10): 564-568
Fischer, P.A.; Schneider, E.; Jacobi, P.; Maxion, H. 1973: Combination therapy of Parkinson's syndrome using L-dopa and a decarboxylase inhibitor Die Medizinische Welt 24(45): 1742-1746
Matussek, N.; Angst, J.; Benkert, O.; Gmür, M.; Papousek, M.; Rüther, E.; Woggon, B. 1974: The effect of L-5-hydroxytryptophan alone and in combination with a decarboxylase inhibitor (Ro-4-4602) in depressive patients Advances in Biochemical Psychopharmacology 11: 399-404
Matussek, N.; Benkert, O.; Schneider, K.; Otten, H.; Pohlmeier, H. 1970: Effect of a decarboxylase inhibitor (Ro 4-4602) in combination with L-dopa on inhibited depressions Arzneimittel-Forschung 20(7): 934-935
Wajsbort, J.; Hemli, J.A.; Alfandary, I.; Yahel, M.; Siegfried, J. 1971: Clinical studies on the treatment of parkinsonism with the L-dopa and decarboxylase inhibitor Ro-4-4602 association Wiener Medizinische Wochenschrift 121(42): 741-745
De Divitiis, E.; Cerillo, A.; Tata, M.R.; Decina, A. 1973: Therapeutic association of L-dopa and an inhibitor of peripheral decarboxylase in Parkinsonism. Preliminary results Acta Neurologica 28(2): 208-212
Eisenlohr, J.J.; Gehlen, W. 1974: Long-term study on the anti-rigidity effect of L-dopa and a decarboxylase inhibitor (ro 8-0576) Münchener Medizinische Wochenschrift 116(28): 1353-1356
Hui, K.S. 1976: The effect of thiazol-4-yimethoxyamine, a histidine decarboxylase inhibitor, on the development of morphine tolerance and physical dependance in mice Experientia 32(10): 1313-1315
Eisenlohr, J.J.; Gehlen, W. 1975: Changes of blood pressure, pulse and electrolytes following long-term treatment of Parkinsonism using Ro 8-0576 (L-Dopa and decarboxylase inhibitor) Der Nervenarzt 46(3): 128-135
Prakash, N.J.; Schechter, P.J.; Grove, J.; Koch-Weser, J. 1978: Effect of alpha-difluoromethylornithine, an enzyme-activated irreversible inhibitor of ornithine decarboxylase, on L1210 leukemia in mice Cancer Research 38(9): 3059-3062
Rabadeau Dumas, J.L.; Rondot, P.; Cardon, P. 1977: Development of studies on the treatment of parkinsonian syndromes with levodopa. II. Long-term effects of L-DOPA alone or in combination with a decarboxylase inhibitor Therapie 32(2): 161-172
Bergonzi, P.; Chiurulla, C.; Gambi, D.; Mennuni, G.; Pinto, F. 1975: L-dopa plus dopa-decarboxylase inhibitor. Sleep organization in Parkinson's syndrome before and after treatment Acta Neurologica Belgica 75(1): 5-10
Guillard, A. 1972: Treatment of Parkinson syndromes with L-Dopa and the association of L-Dopa and a decarboxylase inhibitor Bruxelles Medical 52(10): 673-680
Gauthier, G.; de Ajuriaguerra, J.; Geissbuhler, F.; Simona, B.; Constantinidis, J.; Yanniotis, G.; Krassoievitch, M.; Eisenring, J.J.; Tissot, R. 1971: Substitutive therapy in Parkinson's syndromes. L-dopa plus peripheral decarboxylase inhibitor or 3-0-methyl dopa? La Presse Medicale 79(3): 91-92
Pontiroli, A.E.; Castegnaro, E.; Vettaro, M.P.; Viberti, G.C.; Pozza, G. 1977: Stimulatory effect of the dopa-decarboxylase inhibitor Ro 4-4602 on prolactin release; inhibition by l-dopa, metergoline, methysergide and 2-Br-alpha-ergocryptine Acta Endocrinologica 84(1): 36-44
Verma, A.K.; Boutwell, R.K. 1977: Vitamin a acid (retinoic acid), a potent inhibitor of 12-O-tetradecanoyl-phorbol-13-acetate-induced ornithine decarboxylase activity in mouse epidermis Cancer Research 37(7 Part 1): 2196-2201
Geissbuhler, F.; Eisenring, J.J.; Friedli, P.; Bartholini, G.; Tissot, R. 1972: Cerebral and peripheral L-dopa uptake in patients with parkinsonian, depressive or manic syndromes administered L-dopa by perfusion combined or not with a decarboxylase inhibitor. Pharmacological effects L'Encephale 61(2): 127-148